Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Head and neck cancer cells label free proteomics

ABSTRACT: label-free proteomics for EIF3B knockdown and Control Fadu cells

ORGANISM(S): Homo Sapiens

SUBMITTER: Liang Zhou

PROVIDER: PXD021532 | iProX | Thu Sep 17 00:00:00 BST 2020

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Eukaryotic translation initiation factor 3 subunit B promotes head and neck cancer via CEBPB translation.

Xu Chengzhi C Shen Yupeng Y Shi Yong Y Zhang Ming M Zhou Liang L

Cancer cell international 20220422 1

<h4>Background</h4>Head and neck squamous cell carcinoma (HNSCC) is the sixth most common cancer type worldwide. Deregulation of mRNA translation is a frequent feature of cancer. Eukaryotic translation initiation factor 3 subunit B (EIF3B) has been reported as an oncogene; however, its role in HNSCC has yet to be fully elucidated.<h4>Methods</h4>In this study, the clinical significance of EIF3B expression was analyzed based on TCGA datasets. Then, EIF3B expression was knocked down and its role i ...[more]

PMID: 35459206

Similar Datasets

Impact of label-free technologies in head and neck cancer circulating tumour cells.

Project description:BackgroundThe ability to identify high risk head and neck cancer (HNC) patients with disseminated disease prior to presenting with clinically detectable metastases holds remarkable potential. A fraction of circulating tumour cells (CTCs) are invasive cancer cells which mediate metastasis by intravasation, survival and extravasation from the blood stream to metastatic sites. CTCs have been cleared by the FDA for use as surrogate markers of overall survival and progression free survival for breast, prostate and colorectal cancers using the CellSearch® system. However, the clinical significance of CTCs in head and neck cancer patients has yet to be determined. There has been a significant shift in CTC enrichment platforms, away from exclusively single marker selection, to epitope-independent systems.MethodsThe aim of this study was to screen advanced stage HNC patients by the CellSearch® platform and utilise two other epitope-independent approaches, ScreenCell® (microfiltration device) and RosetteSep™ (negative enrichment), to determine how a shift to such methodologies would enable CTC enrichment and detection.ResultsIn advanced stage HNC patients, single CTCs were detected in 8/43 (18.6%) on CellSearch®, 13/28 (46.4%) on ScreenCell® and 16/25 (64.0%) by RosetteSep™ (the latter could also detect CTC clusters). Notably, in patients with suspicious lung nodules, too small to biopsy, CTCs were found upon presentation. Moreover, CTCs were readily detected in advanced stage HNC patients.ConclusionThe epitope-independent platforms detected higher CTC numbers and clusters. Further studies are needed to ascertain whether CTCs can be used as independent prognostic markers for HNCs.

| S-EPMC5342074 | biostudies-literature

Label-free single-cell RNA Multiplexing leveraging genetic variability

Project description:Label-free single-cell RNA Multiplexing leveraging genetic variability

| PRJNA1040187 | ENA

Label-free melanoma phenotype classification using AI-based morphological profiling

Project description:Label-free melanoma phenotype classification using AI-based morphological profiling

| PRJNA1140860 | ENA

Label-free single-cell RNA Multiplexing leveraging genetic variability [scRNA-seq]

Project description:Label-free single-cell RNA Multiplexing leveraging genetic variability [scRNA-seq]

| PRJNA1040191 | ENA

Immune profiling and label-free detection of 2D MXenes at the single-cell and tissue level

Project description:There is a critical unmet need to image 2D materials within single cells and tissues. Here we propose a versatile label-free single-cell detection strategy based on mass cytometry. We use single-cell mass cytometry by time-of-flight (CyTOF), imaging mass cytometry, and multiplexed ion beam imaging by time-of-flight (MIBI-TOF) with three representative MXenes. Nb4C3, Mo2Ti2C3, and Ta4C3 were selected to ensure mass-detection within the range and to avoid overlap with currently available tags. We demonstrated their biocompatibility, detection, and quantification in 16 primary human immune cell subpopulations also showing the impact of MXene lateral size on the detection signal and cell binding. We report the biological and immune functional compatibility of MXenes. In vivo biodistribution experiments in mice using a mixture of MXenes revealed their presence in liver, blood, spleen, and lungs. Lastly, we applied MIBI-TOF to capture the presence of MXenes in different organs. The label-free detection of 2D materials by mass cytometry at the single cell level, on multiple subpopulations and in multiple organs in vivo opens exciting new opportunities in biomedicine.

2025-04-01 | GSE200036 | GEO

Label-free single-cell RNA Multiplexing leveraging genetic variability [bulk RNA-seq]

Project description:Label-free single-cell RNA Multiplexing leveraging genetic variability [bulk RNA-seq]

| PRJNA1040192 | ENA

HMEC Label-retaining cells

Project description:Gene expression after mammosphere culture, label-retaining cells

| EGAD00010001968 | EGA

High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells

Project description:High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells

| PRJNA836891 | ENA

Niemann-Pick type c1 label-free proteomics

Project description:1) AJS-ESI source comparison of 2, 10 and 20ug of HeLa digest 2) Label-free analysis of 11-week NPC1 null mice and control for unfractionated cerebellum and cerebral cortex 3) Label-free analysis of 11-week NPC1 null mice and control for fractionated cerebellum

2018-02-25 | MSV000082102 | MassIVE

HMEC Non-label-retaining cells

Project description:Gene expression after mammosphere culture, non-label-retaining cells

| EGAD00010001966 | EGA